You're signed outSign in or to get full access.
Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC is an SEC-registered investment adviser founded in 2017 by Michael Cho and Jonathan Chu. Headquartered in New York, NY, the firm manages portfolios for institutional and high net worth clients with a focus on public equity markets. As of 2025, Affinity Asset Advisors has approximately 10 employees, the majority of whom are investment professionals.
Investment Strategy
Affinity Asset Advisors, LLC primarily employs a long/short equity investment strategy, focusing on identifying mispriced securities within the healthcare, biotechnology, and technology sectors. The firm conducts deep fundamental research and seeks to generate alpha by balancing long positions in high-conviction growth opportunities with short positions in overvalued or structurally challenged companies. Risk management and diversification are integral to their approach, aiming to achieve strong risk-adjusted returns for clients.
Latest 13F Filing Activity
Affinity Asset Advisors, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 69 equity positions and 14 options positions with a total 13F market value of $732M. The fund increased holdings in Insmed Inc., Blueprint Medicines Corp., Verona Pharma PLC among other positions. Affinity Asset Advisors, LLC reduced exposure to SPDR S&P 500 Etf TR, Apogee Therapeutics Inc., Centessa Pharmaceuticals PLC among others.
Top Holdings
Equity Positions (69)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
V VRNA | VERONA PHARMA PLC | 7.88% | $57.7M | 610,000 | $16.18 | $94.58 | +$18.6M |
I INSM | INSMED INC | 6.53% | $47.8M | 475,000 | $92.42 | $100.64 | +$37.1M |
X XENE | XENON PHARMACEUTICALS INC | 4.70% | $34.4M | 1,100,000 | $39.02 | $31.30 | -$10.1M |
A ACLX | ARCELLX INC | 4.45% | $32.6M | 495,000 | $44.28 | $65.85 | -$2.2M |
B BPMC | BLUEPRINT MEDICINES CORP | 4.38% | $32.0M | 250,000 | $128.18 | $128.18 | +$32.0M |
Options Positions (14)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
E EXEL | EXELIXIS INC | New | Put | $19.8M | 4,500 | $44.08 | $44.08 | +4,500 | +$19.8M |
A AMGN | AMGEN INC | Sold | Call | $11.2M | 400 | $279.21 | $289.73 | -300 | -$10.6M |
C CRSP | CRISPR Therapeutics AG | New | Call | $9.7M | 2,000 | $48.64 | $48.64 | +2,000 | +$9.7M |
E EXEL | EXELIXIS INC | Bought | Call | $6.6M | 1,500 | $44.08 | $37.64 | +150 | +$1.6M |
C CAPR | CAPRICOR THERAPEUTICS INC | New | Put | $1.7M | 1,750 | $9.93 | $9.93 | +1,750 | +$1.7M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more